The Oncology Institute, Inc.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$503M
↑+27.8% +$109Mvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$503M
↑+27.8% +$109Mvs FY2024 (Q1+Q2+Q3+Q4)
Operating profit
$389M
↑+39.3% +$110Mvs FY2024 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q1+Q2+Q3+Q4) | FY2024 (Q1+Q2+Q3+Q4) |
|---|---|---|
| Revenue | $503M | $393M |
| COGS | $0 | $0 |
| Gross Profit | $503M | $393M |
| R&D | $0 | $0 |
| SG&A | $106M | $108M |
| D&A | $7M | $6M |
| Other OpEx | $1M | $104K |
| Operating Income | $389M | $279M |
| Interest Exp. | $11M | $7M |
| Other Non-Op | $378M | $272M |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · TOI · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)